Mariner
SABS icon

Mariner’s SAB Biotherapeutics SABS Stock Holding History

Mariner’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,900
Closed -$47.4K – 3228
2023
Q4 		$47.4K Hold
6,900
– – ﹤0.01% 2942
2023
Q3 		$43.5K Hold
6,900
– – ﹤0.01% 2783
2023
Q2 		$57.3K Hold
6,900
– – ﹤0.01% 2701
2023
Q1 		$30K Hold
6,900
– – ﹤0.01% 2696
2022
Q4 		$41K Hold
6,900
– – ﹤0.01% 2628
2022
Q3 		$48K Buy
+6,900
New +$68.5K ﹤0.01% 2313

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Mariner's SABS Position: Q1 2024 in Review

Mariner sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 6,900 shares — an estimated $47.4K sold.

Mariner first reported a position in SABS in Q3 2022 and held it in 6 quarters. The position peaked at $57.3K in Q2 2023. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Mariner reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Mariner sold 6,900 SAB Biotherapeutics shares in Q1 2024, an estimated $47.4K.
  • Mariner first reported a position in SAB Biotherapeutics in Q3 2022 and held it in 6 quarters.
  • Mariner's SAB Biotherapeutics position peaked at $57.3K in Q2 2023.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Mariner's 13F filing for Q1 2024, filed 15 May 2024.